NeoGenomics, Inc. $NEO Shares Acquired by California State Teachers Retirement System

California State Teachers Retirement System increased its stake in NeoGenomics, Inc. (NASDAQ:NEO) by 56.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 194,103 shares of the medical research company’s stock after purchasing an additional 70,320 shares during the quarter. California State Teachers Retirement System’s holdings in NeoGenomics were worth $1,440,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. First Horizon Corp lifted its stake in NeoGenomics by 52.6% in the 4th quarter. First Horizon Corp now owns 2,509 shares of the medical research company’s stock worth $30,000 after acquiring an additional 865 shares in the last quarter. Headlands Technologies LLC purchased a new position in NeoGenomics during the 2nd quarter valued at about $32,000. Caitong International Asset Management Co. Ltd increased its holdings in shares of NeoGenomics by 110.2% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 2,968 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 1,556 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of NeoGenomics in the 4th quarter valued at about $39,000. Finally, Smartleaf Asset Management LLC lifted its position in shares of NeoGenomics by 77.7% in the fourth quarter. Smartleaf Asset Management LLC now owns 3,466 shares of the medical research company’s stock worth $42,000 after purchasing an additional 1,515 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Insider Buying and Selling at NeoGenomics

In other NeoGenomics news, Director Lynn A. Tetrault sold 5,307 shares of the firm’s stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of $11.29, for a total value of $59,916.03. Following the completion of the sale, the director owned 91,422 shares in the company, valued at approximately $1,032,154.38. This trade represents a 5.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.10% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the stock. Needham & Company LLC upped their price objective on shares of NeoGenomics from $15.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Zacks Research raised shares of NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 31st. Leerink Partners raised shares of NeoGenomics from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $12.00 to $25.00 in a research note on Wednesday, April 29th. Benchmark boosted their price target on shares of NeoGenomics from $11.00 to $16.00 and gave the company a “buy” rating in a report on Friday, July 24th. Finally, TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research note on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, NeoGenomics presently has a consensus rating of “Moderate Buy” and an average price target of $16.71.

NeoGenomics Trading Down 0.2%

Shares of NEO stock opened at $16.39 on Friday. NeoGenomics, Inc. has a 12 month low of $5.94 and a 12 month high of $16.92. The company has a quick ratio of 3.35, a current ratio of 3.60 and a debt-to-equity ratio of 0.48. The business’s 50 day moving average is $13.88 and its two-hundred day moving average is $10.92. The company has a market cap of $2.11 billion, a PE ratio of -40.98 and a beta of 1.74.

NeoGenomics (NASDAQ:NEO) last announced its earnings results on Tuesday, July 28th. The medical research company reported $0.05 EPS for the quarter, topping the consensus estimate of $0.03 by $0.02. The firm had revenue of $201.66 million for the quarter, compared to the consensus estimate of $196.93 million. NeoGenomics had a negative net margin of 6.77% and a negative return on equity of 1.99%. The business’s quarterly revenue was up 11.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.03 EPS. Equities analysts predict that NeoGenomics, Inc. will post -0.09 EPS for the current year.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.